Phosphonic acid based prodrugs of PMEA and its analogues
Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: wherein: M and V are cis to one another and MPO 3 H 2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxy propyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, 9-(2-phosphonylmethoxy ethyloxy)adenine, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, and (S)-9-(3-fluoro-2-phosphonyl methoxypropyl)adenine; V is selected from a group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, and 3-thienyl, all optionally substituted with 1-3 substituents selected from a group consisting of F, Cl, Br, C1-C3 alkyl, CF 3 and OR 6 ; R 6 is selected from the group consisting of C1-C3 alkyl, and CF 3 ; and pharmaceutically acceptable salts thereof.
1. An isolated compound of Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
MPO 3 H 2 is a phosphonic acid selected ftom the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxypropyl)adenine, 9-(2-phosphonylmethoxyethyloxy)adenine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, and (S)-9-(3-fluoro-2-phosphonyl-methoxypropyl) adenine;
V is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, and 3-thienyl, all optionally substituted with 1–3 substituents selected from the group consisting of F, Cl, Br, C1–C3 alkyl, CF 3 and OR 6 ; and
R 6 is selected from the group consisting of C1–C3 alkyl, and CF 3 ; wherein said compound has S stereochemistry where V is attached and is isolated apart from the corresponding stereoisomer having R stereochemistry where V is attached, and wherein said compound has greater than 96% diastereomeric purity.
2. The compound of claim 1 , wherein MPO 3 H 2 is selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine and (R)-9-(2-phosphonylmethoxypropyl)adenine.
3. The compound of claim 1 , wherein V is selected from the group consisting of phenyl, 3-pyridyl and 4-pyridyl, all optionally substituted with 1–2 substituents selected from a group consisting of F, Br, Cl, CH 3 , OCH 3 , and CF 3 .
4. The compound of claim 1 , wherein V is selected from the group consisting of 4-pyridyl, 2-bromophenyl, and 3-chlorophenyl.
5. The compound of claim 3 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 5 selected from the group consisting of a pharmaceutically acceptable salt formed with an acid selected from the group consisting of acetic acid, hydrobromic acid, hydrochloric acid, citric acid, maleic acid, methanesulfonic acid, nitric acid, phosphoric acid, succinic acid, sulfuric acid, and tartaric acid.
7. The compound of claim 6 selected from the group consisting of a pharmaceutically acceptable salt formed with an acid selected from the group consisting of methanesulfonic acid and succinic acid.
8. The compound of claim 7 , wherein said salt is formed with methanesulfonic acid.
9. A method of treating Hepatitis B in an animal in need thereof, said method comprising administering to the animal the compound of claim 1 .
10. The method of claim 9 , wherein said compound has Formula IV:
or a pharmaceutically acceptable salt thereof.
11. The method of claim 9 , wherein MPO 3 H 2 is 9-(2-phosphonylmethoxyethyl)adenine and V is selected from the group consisting of 4-pyridyl, 2-bromophenyl, and 3-chlorophenyl.
12. The method of claim 9 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
13. A method of treating Hepatitis B in an animal in need thereof, said method comprising administering to the animal the compound of claim 1 and a second agent, wherein said second agent is an antiviral agent, and wherein said second agent is effective for treating Hepatitis B.
14. The method of claim 13 , wherein said antiviral agent is selected from the group consisting of Vidarabine; Zidovudine; Stavudine; Didanosine; ddA; Zalcitabine; L-ddC; L-FddC; L-d4C; Lamivudine; Ribavirin; FIAU; FIAC; BHCG; BvaraU; E-5-(2-bromovinyl)-2′-deoxyuridine; TFT; Zonavir; CDG; DAPD; FDOC; d4C; d4T; DXG; FEAU; FLG; FLT; Clevudine; Coviracil; Entecavir; Cytallene; Oxetanocin A; Oxetanocin G; NK 84-0218; ddAPR; Cyclobut A; Cyclobut G (Lobucavir); Floxuridine; dFdC; araC; 5-bromodeoxyuridine; IDU; CdA; F-ara-A; ACV; CCV; Penciclovir; Buciclovir; Foscamet; PPA; PMEA; PMEDAP; HPMPC; HPMPA; FPMPA; PMPA; araT; FMdC; AlCAR; AM365; L-dT; L-dC, beta-L-2′-deoxycytosine, a valine prodrug of beta-L-2′-deoxycytosine; ACH 126,443; ddI; ddA; ddC; MCC478; an Interferon; a Pegylated interferon famciclovir; XTL001; an HBV DNA vaccine; Racivir; Robustaflavone; 9-(arabinofuranosyl)-2,6-diaminopurine; 9-(2′-deoxyribofuranosyl)-2,6-diaminopurine; 9-(2′-deoxy-2′-fluororibofuranosyl)-2,6-diaminopurine; 9-(arabinofuranosyl)guanine; 9-(2′-deoxyribofuranosyl)guanine; 9-(2′-deoxy 2′-fluororibofuranosyl)guanine; and a human monoclonal antibody.
15. The method of claim 14 , wherein said antiviral agent is selected from the group consisting of Lamivudine, Entecavir, Coviracil, DAPD, Clevudine, AM365, L-dT, L-dC, ACH 126,443, MCC478, Lobucavir, Foscarnet, PPA, interferon alpha, and pegylated interferon alfa.
16. The method of claim 13 , wherein said compound has Formula IV:
or a pharmaceutically acceptable salt thereof;
and said antiviral agent is selected from the group consisting of Lamivudine, Entecavir, Coviracil, DAPD, Clevudine, AM365, L-dT, L-dC, ACH 126,443, MCC478, Lobucavir, Foscarnet, PPA, interferon alpha, and pegylated interferon alfa.
17. The method of claim 16 , wherein said antiviral agent is selected from the group consisting of Lamivudine, Entecavir, Coviracil, DAPD, Clevudine, AM365, L-dT, L-dC, and ACH 126,443 and pharmaceutically acceptable salts thereof.
18. The method of claim 16 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
19. The method of claim 13 , wherein said compound is
or a pharmaceutically acceptable salt thereof.
20. The method of claim 18 , wherein said antiviral agent is Lamivudine, or a pharmaceutically acceptable salt thereof.
21. The method of claim 16 , wherein said antiviral agent is selected from the group consisting of interferon alpha and pegylated inteferon alpha.
22. The method of claim 13 , wherein said antiviral agent and said compound are administered separately.
23. The method of claim 13 , wherein said antiviral agent and said compound are administered simultaneously.
24. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 1 and a pharmaceutically acceptable excipient.
25. The phannaceutical composition of claim 24 , wherein said compound has Formula IV:
or a pharmaceutically acceptable salt thereof.
26. The phannaceutical composition of claim 24 , wherein said compound is:
or a pharmaceutically acceptable salt thereof.
27. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound of claim 1 ;
a pharmaceutically effective amount of a second agent wherein said second agent is an antiviral agent or salt thereof; and
a pharmaceutically acceptable excipient.
28. The pharmaceutical composition of claim 27 , wherein said antiviral agent is selected from the group consisting of Lamivudine, Entecavir, Coviracil, DAPD, Clevudine, AM365, L-dT, L-dC, ACH 126,443, MCC478, Lobucavir, Foscarnet, PPA, interferon alpha, and pegylated interferon alfa.
29. The pharmaceutical composition of claim 27 , wherein said compound has Formula IV:
or a pharmaceutically acceptable salt thereof.
30. The pharmaceutical composition of claim 27 , wherein said compound is:
or a pharmaceutically acceptable salt thereof.